Skip to content
by Legal Desire
7 December 2023

Latham & Watkins Advises Cerevel Therapeutics in Acquisition by AbbVie

Advising firms

Deal team

24 lawyers named
LawyerFirmSeniorityPracticeOffice
Charles Ruck Lead Latham & Watkins LLP Partner corporate New York
Daniel Rees Lead Latham & Watkins LLP Partner corporate Orange County
Brian Umanoff Latham & Watkins LLP Associate corporate Not stated
Jack McKay Latham & Watkins LLP Associate corporate Not stated
AJ Blair Latham & Watkins LLP Associate corporate Not stated
Courtney Lem Latham & Watkins LLP Associate corporate Not stated
Danny Del Giorno Latham & Watkins LLP Associate corporate Not stated
Jacob Kempf Latham & Watkins LLP Associate corporate Not stated
Greg Rodgers Latham & Watkins LLP Partner debt Los Angeles
Ryan Gold Latham & Watkins LLP Associate debt New York
Jekkie Kim Latham & Watkins LLP Partner intellectual property Bay Area
Billy Wu Latham & Watkins LLP Associate intellectual property Bay Area
Katharine Moir Latham & Watkins LLP Partner tax Bay Area
Rasha Suleiman Latham & Watkins LLP Associate tax Bay Area
Chad Jennings Latham & Watkins LLP Counsel FDA regulatory Washington, D.C.
Trevor Thompson Latham & Watkins LLP Associate FDA regulatory Washington, D.C.
Betty Pang Latham & Watkins LLP Partner healthcare Bay Area
Maj Vaseghi Latham & Watkins LLP Partner benefits Bay Area
Alisa Hand Latham & Watkins LLP Associate benefits Bay Area
Nimra Syed Latham & Watkins LLP Associate benefits Bay Area
Joshua Holian Latham & Watkins LLP Partner HSR Bay Area
Olivia Zacks Latham & Watkins LLP Associate HSR Bay Area
Heather Deixler Latham & Watkins LLP Partner data privacy Bay Area
Mitch Bennett Latham & Watkins LLP Associate data privacy Bay Area

21 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.

REGISTER FREE SIGN IN

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value
USD 8.70bn (US$8.7 billion)
What the figure measures
Total transaction value
Client
Cerevel TherapeuticsTarget
Counterparties
AbbVie Inc. (Buy-side)